State Street
SPRY icon

State Street’s ARS Pharmaceuticals SPRY Stock Holding History

State Street’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.9M Buy
3,730,623
+85,657
+2% +$737K ﹤0.01% 2159
2026
Q1 		$29.3M Buy
3,644,966
+421,385
+13% +$4.04M ﹤0.01% 2030
2025
Q4 		$37.6M Buy
3,223,581
+328,325
+11% +$3.19M ﹤0.01% 1903
2025
Q3 		$29.1M Buy
2,895,256
+700,763
+32% +$10.1M ﹤0.01% 2033
2025
Q2 		$38.3M Buy
2,194,493
+163,259
+8% +$2.36M ﹤0.01% 1824
2025
Q1 		$25.6M Sell
2,031,234
-718,667
-26% -$8.65M ﹤0.01% 1987
2024
Q4 		$29M Buy
2,749,901
+700,359
+34% +$9.81M ﹤0.01% 2008
2024
Q3 		$29.7M Buy
2,049,542
+193,321
+10% +$2.3M ﹤0.01% 1983
2024
Q2 		$15.8M Buy
1,856,221
+251,671
+16% +$2.23M ﹤0.01% 2288
2024
Q1 		$16.4M Buy
1,604,550
+1,027,570
+178% +$7.66M ﹤0.01% 2290
2023
Q4 		$3.16M Buy
576,980
+40,820
+8% +$179K ﹤0.01% 3152
2023
Q3 		$2.03M Buy
536,160
+97,609
+22% +$641K ﹤0.01% 3327
2023
Q2 		$2.94M Buy
438,551
+309,360
+239% +$2.06M ﹤0.01% 3238
2023
Q1 		$841K Buy
129,191
+43,300
+50% +$333K ﹤0.01% 3593
2022
Q4 		$733K Buy
85,891
+18,300
+27% +$119K ﹤0.01% 3639
2022
Q3 		$357K Hold
67,591
– – ﹤0.01% 3902
2022
Q2 		$287K Sell
67,591
-276,603
-80% -$965K ﹤0.01% 4052
2022
Q1 		$1.21M Buy
344,194
+20,181
+6% +$87.9K ﹤0.01% 3746
2021
Q4 		$2.16M Buy
324,013
+18,944
+6% +$154K ﹤0.01% 3609
2021
Q3 		$3.04M Buy
305,069
+80,750
+36% +$1.99M ﹤0.01% 3489
2021
Q2 		$6.93M Buy
224,319
+32,155
+17% +$1.03M ﹤0.01% 3089
2021
Q1 		$8.38M Buy
+192,164
New +$9.09M ﹤0.01% 2825

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street's SPRY Position: Q2 2026 in Review

State Street increased its ARS Pharmaceuticals (SPRY) stake by 2.4% in Q2 2026, buying an estimated $737K and bringing the position to 3,730,623 shares worth $29.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2159.

State Street first reported a position in SPRY in Q1 2021 and has held it in 22 quarters since. The position peaked at $38.3M in Q2 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • State Street held 3,730,623 shares of ARS Pharmaceuticals worth $29.9M as of Q2 2026.
  • State Street bought 85,657 ARS Pharmaceuticals shares in Q2 2026, an estimated $737K.
  • ARS Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2159 holding.
  • State Street first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • State Street's ARS Pharmaceuticals position peaked at $38.3M in Q2 2025.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.